News Doubts over BACE drugs after Merck ends Alzheimer's trial Decision comes a year after Merck axed EPOCH verubecestat trial
News Axovant CEO David Hung quits after Alzheimer's drug failure Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
News Boehringer latest to axe Alzheimer's drug Company will trial BI 409306 in schizophrenia instead.
News Bad week for dementia R&D after Axovant howler and another f... Axovant misreports trial results, Lundbeck Alzheimer's drug fails
News Pfizer axes Alzheimer's and Parkinson's research Big pharma will continue developing tanezumab painkiller with Lilly
Partner Content Partner Content 2018 Agenda Released: World CNS Summit Targeting Neurodegenerative Diseases
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
